Literature DB >> 10753503

Nitric-oxide-dependent systemic immunosuppression in animals with progressively growing malignant gliomas.

P Hegardt1, B Widegren, H O Sjögren.   

Abstract

The role of nitric oxide (NO) and adherent spleen cells in systemic immunosuppression developing in animals carrying malignant glioma isografts was analyzed. Rats harboring a subcutaneous glioma isograft for 3 weeks were immunized with glioma cells genetically engineered to express IFN-gamma. One week later spleen cells were tested for immune responsiveness in vitro. A decreased cytotoxic activity of NK-cells and T-cells compared to tumor-free animals immunized in parallel was shown. Spleen cell proliferative responses to tumor cells, SEA, and anti-CD3 were all significantly suppressed, as was the production of IFN-gamma and IL-10. Plastic adherent spleen cells from tumor-bearing rats suppressed the SEA-induced proliferative response and the production of IFN-gamma and IL-10 by nonadherent spleen cells from tumor-free rats. A major part of this suppression appears to be dependent on the production of NO because suppression was efficiently counteracted in vitro by the NO-synthase inhibitor N-nitro-l-arginine methyl ester. Moreover, a significantly increased level of nitrite in culture supernatants correlated with the observed suppression. We conclude that the systemic immunosuppression associated with growing gliomas is in part mediated by mechanisms dependent on NO overproduction in adherent spleen cells. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10753503     DOI: 10.1006/cimm.2000.1625

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  9 in total

1.  Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma + vaccination model.

Authors:  Wentao Jia; Colleen Jackson-Cook; Martin R Graf
Journal:  J Neuroimmunol       Date:  2010-05-08       Impact factor: 3.478

Review 2.  Immunosuppressive mechanisms in glioblastoma.

Authors:  Edjah K Nduom; Michael Weller; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

Review 3.  NOS Expression and NO Function in Glioma and Implications for Patient Therapies.

Authors:  Anh N Tran; Nathaniel H Boyd; Kiera Walker; Anita B Hjelmeland
Journal:  Antioxid Redox Signal       Date:  2016-08-25       Impact factor: 8.401

4.  Hypoxia-induced nitric oxide release by luminal cells stimulates proliferation and uPA secretion of myoepithelial cells in a bicellular murine mammary tumor.

Authors:  Martin Alejandro Krasnapolski; Catalina Lodillinsky; Elisa Bal De Kier Joffé; Ana María Eiján
Journal:  J Cancer Res Clin Oncol       Date:  2015-02-17       Impact factor: 4.553

Review 5.  Current state and future prospects of immunotherapy for glioma.

Authors:  Neha Kamran; Mahmoud S Alghamri; Felipe J Nunez; Diana Shah; Antonela S Asad; Marianela Candolfi; David Altshuler; Pedro R Lowenstein; Maria G Castro
Journal:  Immunotherapy       Date:  2018-02-01       Impact factor: 4.196

6.  Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects.

Authors:  Alexander L Rakhmilevich; Mark J Baldeshwiler; Tyler J Van De Voort; Mildred A R Felder; Richard K Yang; Nicholas A Kalogriopoulos; David S Koslov; Nico Van Rooijen; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2012-03-06       Impact factor: 6.968

Review 7.  Therapeutic vaccination with tumor cells that engage CD137.

Authors:  Karl Erik Hellstrom; Ingegerd Hellstrom
Journal:  J Mol Med (Berl)       Date:  2003-02-08       Impact factor: 4.599

8.  Glioma-associated cancer-initiating cells induce immunosuppression.

Authors:  Jun Wei; Jason Barr; Ling-Yuan Kong; Yongtao Wang; Adam Wu; Amit K Sharma; Joy Gumin; Verlene Henry; Howard Colman; Raymond Sawaya; Frederick F Lang; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

9.  Participation of the NO/cGMP/K+ATP pathway in the antinociception induced by Walker tumor bearing in rats.

Authors:  A L R Barbosa; C A Pinheiro; G J Oliveira; J N L Torres; M O Moraes; R A Ribeiro; M L Vale; M H L P Souza
Journal:  Braz J Med Biol Res       Date:  2012-03-29       Impact factor: 2.590

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.